The recently published report on the interim evaluation of IHI covers the period from December 2021 to June 2023 and the final evaluation of IMI2. The Innovative Health Initiative (IHI) is a partnership between the European Union, represented by the European Commission (EC), and five European associations of life science industries, including the European Federation of Pharmaceutical Industries and Associations (EFPIA), Vaccines Europe, COCIR, MedTech Europe and EuropaBio. It builds on the experience of the Innovative Medicines Initiative (IMI2), which ran from 2014 to 2020 and was comprised of the EC and EFPIA only.
The report is organised along five evaluation criteria (relevance, coherence, efficiency, effectiveness, EU-added value) and four partnership-specific criteria (additionality, directionality, international positioning and visibility, and transparency and openness). The methods used for the evaluations included desk research, stakeholder interviews, and two case studies.